Study of Tadalafil vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology

Overview

About this study

The primary study objectives are to examine the therapeutic potential of Tadalafil in improving endothelial function, hemodynamic capabilities, and end-organ function in patients who have previously undergone a Fontan Palliation.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Patients ≥ 18 years old.

- Have previously undergone a Fontan Palliation.

- Able to exercise using a supine bike.

- Able to undergo an MRI.

- Ability and willingness to provide written consent.

Exclusion Criteria:

- Patients < 18 years old.

- Current intravenous inotropic drugs.

- Current use of pulmonary vasodilators or nitrates.

- Unable to exercise.

- Pregnancy or lactating.

- Unable or unwilling to consent.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 1/12/24. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Alexander Egbe, M.B.B.S., M.P.H.

Open for enrollment

Contact information:

Adult Congenital Research Program

(507) 293-2565

RSTACHDRESPRG@mayo.edu

More information

Publications

Publications are currently not available